Genome&Company Logo

Genome&Company

Clinical-stage biopharma developing cancer therapies using microbiome, immune inhibitors, and ADCs.

314130 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
경기도 수원시 영통구 창룡대로256번길 50 7층, 8층, 수원시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Genome & Company is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics. The company's core research and development programs are centered on microbiome-based pharmaceuticals, novel immune checkpoint inhibitors, and antibody-drug conjugates (ADCs). Its primary therapeutic area is immuno-oncology, aiming to develop new treatments for various cancers. Genome & Company utilizes its proprietary drug discovery platform to advance its pipeline through clinical trials and strategic partnerships, including the out-licensing of its drug candidates to global pharmaceutical firms.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Genome&Company and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-21 00:00
M&A Activity
주요사항보고서(타법인주식및출자증권양도결정)
Korean 20.7 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.8 MB

Automate Your Workflow. Get a real-time feed of all Genome&Company filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Genome&Company via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Pluri Inc. Logo
Develops placenta-based cell therapeutics using a proprietary 3D cell-expansion platform.
Israel PLUR
A global supplier of generic APIs using AI to accelerate drug development.
South Korea 041910
Poltreg S.A. Logo
Pioneering T-regulatory cell therapies for autoimmune diseases like diabetes, MS, and ALS.
Poland PTG
PolyPeptide Group AG Logo
A global CDMO specializing in peptide and oligonucleotide APIs for pharma and biotech partners.
Switzerland PPGN
Develops sensitive point-of-care biomarker diagnostics for human and animal health.
South Korea 335810
A global CDEMO offering end-to-end solutions for antibody therapeutics and biologics.
South Korea 334970
Develops affordable biosimilars and novel antibody drugs for life-threatening diseases.
Singapore 950210
Develops protein-based immunotherapies for metabolic diseases, immune disorders, and cancer.
South Korea 296160
PROTEINA CO.,LTD. Logo
A biotech firm specializing in proteomics for drug discovery and diagnostics in oncology.
South Korea 468530
PROTIA INC. Logo
Develops IVD kits and instruments for allergy, POCT, infectious & autoimmune diseases.
South Korea 303360

Talk to a Data Expert

Have a question? We'll get back to you promptly.